Condensed Consolidated Balance Sheets (Unaudited) - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Current assets
Cash and cash equivalents	$ 122,401,000	$ 123,436,000
Short-term marketable securities (amortized cost of $292,556 and $564,036, respectively)	292,639,000	564,833,000
Accounts receivable, net	17,122,000	10,047,000
Inventory	18,231,000	14,063,000
Prepaid expenses and other current assets	16,634,000	14,535,000
Total current assets	467,027,000	726,914,000
Long-term assets
Property and equipment, net	87,820,000	39,692,000
Operating lease right-of-use assets	89,446,000	99,350,000
Long-term marketable securities (amortized cost of $217,455 and $118,429, respectively)	217,379,000	118,525,000
Restricted cash	2,138,000	2,138,000
Intangible assets, net	8,955,000	10,225,000
Goodwill	118,972,000	118,972,000
Other assets	870,000	598,000
Total assets	992,607,000	1,116,414,000
Current liabilities
Accounts payable	8,252,000	3,237,000
Accrued liabilities	17,034,000	13,162,000
Accrued compensation and benefits	12,034,000	11,950,000
Current portion of operating lease liabilities	5,108,000	3,529,000
Current portion of deferred revenue	79,954,000	73,319,000
Total current liabilities	122,382,000	105,197,000
Long-term liabilities
Operating lease liabilities, less current portion	108,044,000	104,333,000
Deferred revenue, less current portion	110,638,000	163,618,000
Total liabilities	341,064,000	373,148,000
Commitments and contingencies (Note 9)
Shareholders’ equity
Preferred stock: $0.0001 par value, 10,000,000 shares authorized at September 30, 2021 and December 31, 2020; no shares issued and outstanding at September 30, 2021 and December 31, 2020
Common stock: $0.0001 par value, 340,000,000 shares authorized at September 30, 2021 and December 31, 2020; 141,027,487 and 137,646,896 shares issued and outstanding at September 30, 2021 and December 31, 2020, respectively	14,000	14,000
Additional paid-in capital	1,308,946,000	1,253,971,000
Accumulated other comprehensive gain	7,000	893,000
Accumulated deficit	(657,458,000)	(511,612,000)
Total Adaptive Biotechnologies Corporation shareholders’ equity	651,509,000	743,266,000
Noncontrolling interest	34,000
Total shareholders’ equity	651,543,000	743,266,000
Total liabilities and shareholders’ equity	$ 992,607,000	$ 1,116,414,000